


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231



On

TOWNSEND and TOWNSEND and CREW LLP

By:

Attorney Docket No.: 021044-001210US

PATENT

RECEIVED

JUL 02 2002

TECH CENTER 1600/2900

COPY OF PAPERS
ORIGINALLY FILED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HITOSHI et al.

Application No.: 10/026,021

Filed: December 21, 2001

For: SAK: MODULATION OF
CELLULAR PROLIFERATION FOR
TREATMENT OF CANCER

Examiner: Not yet assigned

Art Unit: 1646

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

RECEIVED

AUG 12 2002

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Annette S. Parent
Reg. No. 42,058

~~TOWNSEND and TOWNSEND and CREW LLP~~

Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
ASP:dk

OTPE
JUN 27 2002
U.S. PATENT & TRADEMARK OFFICE

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/026,021
Filing Date	December 21, 2001
First Named Inventor	Hitoshi, Yasumichi
Art Unit	1646
Examiner Name	Not yet assigned
Attorney Docket Number	021044-001210US

RECEIVED

JUL 02 2002

TECH CENTER 1800/2900

U.S. PATENT DOCUMENTS

Examiner	Cite No.	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-5,650,501	Jul. 22, 1997	Dennis et al.	
	AB	US-5,976,893	Nov. 2, 1999	Dennis et al.	
	AC	US-			
	AD	US-			
	AE	US-			
	AF	US-			
	AG	US-			
	AH	US-			
	AI	US-			
	AJ	US-			
	AK	US-			
	AL	US-			
	AM	US-			
	AN	US-			
	AO	US-			
	AP	US-			
	AQ	US-			
	AR	US-			
	AS	US-			
	AT	US-			

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

AUG 1 2 2002

TECH CENTER 1800/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)				
	AU						
	AV						
	AW						
	AX						
	AY						
	AZ						
	BA						
	BB						

Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 20 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1357767 v1

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/026,021
Filing Date	December 21, 2001
First Named Inventor	Hitoshi, Yasumichi
Art Unit	1646
Examiner Name	Not yet assigned
Attorney Docket Number	021044-001210US

RECEIVED

JUL 02 2002

TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BC	Kam <i>et al.</i> , "Human SAK related to the PLK/polo family of cell cycle kinases shows high mRNA expression in testis," <i>Oncology Reports</i> 4: 505-510 (1997).	
	BD	"Chaturvedi <i>et al.</i> , "Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway," <i>Oncogene</i> 18: 4047-4054 (1999).	
	BE	Brown <i>et al.</i> , "A human Cds1-related kinase that functions downstream of ATM protein in the cellular response to DNA damage," <i>Proc. Natl. Acad. Sci. USA</i> 96: 3745-3750 (1999).	
	BF	Blasina <i>et al.</i> , "A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase," <i>Current Biology</i> 8: 1-10 (1998).	
	BG	Hudson <i>et al.</i> , "Late mitotic failure in mice lacking Sak, a polo-like kinase," <i>Current Biology</i> 11: 441-446 (2001)	
	BH	Glover <i>et al.</i> , "Polo-like kinases: a team that plays throughout mitosis," <i>Genes & Dev.</i> 12: 3777-3787 (1998).	
	BI	Hudson <i>et al.</i> , "Sak kinase gene structure and transcriptional regulation," <i>Gene</i> 241: 65-73 (2000).	
	BJ	Matsuoka <i>et al.</i> , "Linkage of ATM to Cell Cycle Regulation by the Chk2 Protein Kinase," <i>Science</i> 282: 1893-1897 (1998).	
	BK		
	BL		
	BM		

RECEIVED

AUG 12 2002

TECH CENTER 1600/2900
COPY OF PAPERS
ORIGINALLY FILED

Examiner
SignatureDate
Considered

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
SF 1357767 v1